3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
3
Phase 1
3
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
7
Genitourinary
3
Conditions
Prostatic Neoplasms
2
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
66
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
43
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
31
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Nivolumab
24
Triptorelin Pamoate
23
Sunitinib
23
apalutamide
22
Radiation
22
Doxorubicin
20
darolutamide
19
abiraterone
18
Gonadotropin-Releasing Hormone
18
cabozantinib
17
atezolizumab
16
Specimen Handling
16
Radiosurgery
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
capivasertib
×
Genitourinary
×
Clear all
NCT04493853
2026-05-05
CAPItello-281
AstraZeneca
Phase 3
Active not recruiting
1,012 enrolled
NCT03903835
2025-04-09
ProBio
Karolinska Institutet
Phase 3
Recruiting
750 enrolled
NCT05348577
2025-01-27
CAPItello280
AstraZeneca
Phase 3
Active not recruiting
1,035 enrolled